Jeff Aronin Wins the 2019 BIG Innovation Award for Leadership
Paragon Biosciences Chairman and CEO Jeffrey S. Aronin won a 2019 BIG Innovation Award presented by the Business Intelligence Group. The award honors executives whose leadership improves quality of life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190206005182/en/
Jeff Aronin Wins the 2019 BIG Innovation Award for Leadership (Photo: Business Wire)
“This year’s winners show just how deep a role innovation plays in nearly every aspect of business,” said Maria Jimenez, chief operating officer of the Business Intelligence Group. “We are thrilled to be honoring Jeff Aronin as he is leading by example and making real progress on improving the daily lives of so many.”
In his therapeutic focus areas, Jeff Aronin’s companies have been among the most successful at developing medicines for severe diseases which previously had no FDA-approved treatments.
Paragon Biosciences advances that mission through its contribution of Bioscience Innovation CapitalTM: For rare and complex diseases, Paragon analyzes the viability of potential therapies, invests in new biopharmaceutical companies to further develop promising treatments, catalyzes the progress of its portfolio companies through early-incubation services, and provides clinical and regulatory guidance by a team with a near-perfect track record of first-cycle novel drug approvals.
“The Paragon Biosciences team prides itself on our commitment to solving critical medical needs that are underserved by others,” said Mr. Aronin. “The BIG Innovation Award is a testament to the Bioscience Innovation CapitalTM we contribute and my team’s dedication to improving lives.”
For 25 years, Mr. Aronin has led and inspired healthcare innovation. The BIG Innovation Award is just the latest recognition of his leadership in the development of novel therapies. Insights Care magazine recently recognized Mr. Aronin as one of the most influential leaders in healthcare for his extraordinary track record at improving the quality of life of patients with severe diseases, by developing breakthrough medicines to treat those conditions.
“The year ahead holds tremendous opportunity for therapy innovation,” said Mr. Aronin. “In 2019, we plan to make significant investments in AI-enabled life sciences and advanced genetic therapies.”
About Paragon Biosciences:
For severe and complex diseases, Paragon Biosciences researches the viability of potential treatments for unmet patient needs, invests in the development of novel medicines, launches biopharmaceutical companies to further develop those therapies, and supports these new portfolio companies with early-incubation services. After which, the portfolio companies operate independently as they conduct clinical trials and seek FDA approval of improved treatments. Paragon Biosciences is headquartered in Chicago, Illinois. For more information, visit: ParagonBioSci.com.
About Business Intelligence Group:
The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in the business world. The organization’s proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those whose achievements stand above those of their peers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190206005182/en/